Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
1. A method for the treatment of epilepsy comprising administering to a patient in need thereof a therapeutically effective amount of a combination comprising:
(a) a synaptic vesicle protein 2A (“SV2A”) ligand selected from the group consisting of levetiracetam, brivaracetam; and
(b) a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) compound of
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 wherein the SV2A ligand is levetiracetam.
3. The method of claim 1 wherein the SV2A ligand is brivaracetam.
4. The method of claim 1 wherein the combination of the SV2A ligand and the PAM of a mGluR2 compound is administered simultaneously to treat epilepsy.
5. The method of claim 1 wherein the combination of the SV2A ligand and the PAM of a mGluR2 compound is administered separately to treat epilepsy.
6. The method of claim 1 wherein the combination of the SV2A ligand and the PAM of a mGluR2 compound is administered sequentially to treat epilepsy.
7. The method of claim 1 wherein the epilepsy is epilepsy with partial onset seizures.
8. The method of claim 1 wherein the epilepsy is epilepsy with myoclonic seizures.
9. The method of claim 1 wherein the epilepsy is epilepsy with primary generalized tonic-clonic seizures.
10. The method of claim 1 wherein the epilepsy is treatment resistant epilepsy.
11. A method for the treatment of epilepsy comprising administering to a patient in need thereof a therapeutically effective amount of a combination comprising:
(a) a SV2A ligand selected from the group consisting of levetiracetam, brivaracetam; and
(b) a PAM of mGluR2 compound of
or a pharmaceutically acceptable salt thereof.
12. The method of claim 11 wherein the SV2A ligand is levetiracetam.
13. The method of claim 11 wherein the SV2A ligand is brivaracetam.
14. The method of claim 11 wherein the combination of the SV2A ligand and the PAM of a mGluR2 compound is administered simultaneously to treat epilepsy and related disorders.
15. The method of claim 11 wherein the combination of the SV2A ligand and the PAM of a mGluR2 compound is administered separately to treat epilepsy and related disorders.
16. The method of claim 11 wherein the combination of the SV2A ligand and the PAM of a mGluR2 compound is administered sequentially to treat epilepsy and related disorders.
17. The method of claim 11 wherein the epilepsy is epilepsy with partial onset seizures.
18. The method of claim 11 wherein the epilepsy is epilepsy with myoclonic seizures.
19. The method of claim 11 wherein the epilepsy is epilepsy with primary generalized tonic-clonic seizures.
20. The method of claim 11 wherein the epilepsy is treatment resistant epilepsy.